NCT00140426View on ClinicalTrials.gov

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Anorexia Nervosa
Interventions
DRUG

Risperidone

risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.

DRUG

Placebo

Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.

Trial Locations (1)

80218

The Children's Hospital, Denver

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

University of Colorado, Denver

OTHER